191 related articles for article (PubMed ID: 9145869)
21. HIV-1 drug susceptibilities and reverse transcriptase mutations in patients receiving combination therapy with didanosine and delavirdine.
Demeter LM; Meehan PM; Morse G; Gerondelis P; Dexter A; Berrios L; Cox S; Freimuth W; Reichman RC
J Acquir Immune Defic Syndr Hum Retrovirol; 1997 Feb; 14(2):136-44. PubMed ID: 9052722
[TBL] [Abstract][Full Text] [Related]
22. Biological and biochemical anti-HIV activity of the benzothiadiazine class of nonnucleoside reverse transcriptase inhibitors.
Buckheit RW; Fliakas-Boltz V; Decker WD; Roberson JL; Pyle CA; White EL; Bowdon BJ; McMahon JB; Boyd MR; Bader JP
Antiviral Res; 1994 Sep; 25(1):43-56. PubMed ID: 7529014
[TBL] [Abstract][Full Text] [Related]
23. Preclinical evaluation of MKC-442, a highly potent and specific inhibitor of human immunodeficiency virus type 1 in vitro.
Baba M; Shigeta S; Yuasa S; Takashima H; Sekiya K; Ubasawa M; Tanaka H; Miyasaka T; Walker RT; De Clercq E
Antimicrob Agents Chemother; 1994 Apr; 38(4):688-92. PubMed ID: 7518216
[TBL] [Abstract][Full Text] [Related]
24. Structure-based design of HIV protease inhibitors: 5,6-dihydro-4-hydroxy-2-pyrones as effective, nonpeptidic inhibitors.
Thaisrivongs S; Romero DL; Tommasi RA; Janakiraman MN; Strohbach JW; Turner SR; Biles C; Morge RR; Johnson PD; Aristoff PA; Tomich PK; Lynn JC; Horng MM; Chong KT; Hinshaw RR; Howe WJ; Finzel BC; Watenpaugh KD
J Med Chem; 1996 Nov; 39(23):4630-42. PubMed ID: 8917652
[TBL] [Abstract][Full Text] [Related]
25. Targeting delavirdine/atevirdine resistant HIV-1: identification of (alkylamino)piperidine-containing bis(heteroaryl)piperazines as broad spectrum HIV-1 reverse transcriptase inhibitors.
Romero DL; Olmsted RA; Poel TJ; Morge RA; Biles C; Keiser BJ; Kopta LA; Friis JM; Hosley JD; Stefanski KJ; Wishka DG; Evans DB; Morris J; Stehle RG; Sharma SK; Yagi Y; Voorman RL; Adams WJ; Tarpley WG; Thomas RC
J Med Chem; 1996 Sep; 39(19):3769-89. PubMed ID: 8809165
[TBL] [Abstract][Full Text] [Related]
26. The nontoxic tripeptide glycyl-prolyl-glycine amide inhibits the replication of human immunodeficiency virus type 1.
Su J; Andersson E; Horal P; Naghavi MH; Palm A; Wu YP; Eriksson K; Jansson M; Wigzell H; Svennerholm B; Vahlne A
J Hum Virol; 2001; 4(1):1-7. PubMed ID: 11213928
[TBL] [Abstract][Full Text] [Related]
27. Unique thermodynamic response of tipranavir to human immunodeficiency virus type 1 protease drug resistance mutations.
Muzammil S; Armstrong AA; Kang LW; Jakalian A; Bonneau PR; Schmelmer V; Amzel LM; Freire E
J Virol; 2007 May; 81(10):5144-54. PubMed ID: 17360759
[TBL] [Abstract][Full Text] [Related]
28. Delavirdine mesylate, a potent non-nucleoside HIV-1 reverse transcriptase inhibitor.
Freimuth WW
Adv Exp Med Biol; 1996; 394():279-89. PubMed ID: 8815692
[TBL] [Abstract][Full Text] [Related]
29. [Combination of phosphazide and crixivan inhibit replication of HIV-1 strains that are resistant to azidothymidine].
Selimova LM; Kraevskiĭ AA; Galegov GA
Dokl Akad Nauk; 1999 Dec; 369(6):847-9. PubMed ID: 10687056
[No Abstract] [Full Text] [Related]
30. In vitro evaluation of the effect of temporary removal of HIV drug pressure.
Witvrouw M; Pannecouque C; Desmyter J; De Clercq E; Andries K
Antiviral Res; 2000 Jun; 46(3):215-21. PubMed ID: 10867159
[TBL] [Abstract][Full Text] [Related]
31. U-90152, a potent inhibitor of human immunodeficiency virus type 1 replication.
Dueweke TJ; Poppe SM; Romero DL; Swaney SM; So AG; Downey KM; Althaus IW; Reusser F; Busso M; Resnick L
Antimicrob Agents Chemother; 1993 May; 37(5):1127-31. PubMed ID: 7685995
[TBL] [Abstract][Full Text] [Related]
32. Combinative interactions of a human immunodeficiency virus (HIV) Tat antagonist with HIV reverse transcriptase inhibitors and an HIV protease inhibitor.
Connell EV; Hsu MC; Richman DD
Antimicrob Agents Chemother; 1994 Feb; 38(2):348-52. PubMed ID: 7514858
[TBL] [Abstract][Full Text] [Related]
33. Combinations of reverse transcriptase, protease, and integrase inhibitors can be synergistic in vitro against drug-sensitive and RT inhibitor-resistant molecular clones of HIV-1.
Beale KK; Robinson WE
Antiviral Res; 2000 Jun; 46(3):223-32. PubMed ID: 10867160
[TBL] [Abstract][Full Text] [Related]
34. Progress of bis(heteroaryl)piperazines (BHAPs) as non-nucleoside reverse transcriptase inhibitors (NNRTIs) against human immunodeficiency virus type 1 (HIV-1).
Xu H
Mini Rev Med Chem; 2010 Jan; 10(1):62-72. PubMed ID: 20380641
[TBL] [Abstract][Full Text] [Related]
35. Pyrido [1,2a] indole derivatives identified as novel non-nucleoside reverse transcriptase inhibitors of human immunodeficiency virus type 1.
Taylor DL; Ahmed PS; Chambers P; Tyms AS; Bedard J; Duchaine J; Falardeau G; Lavallée JF; Brown W; Rando RF; Bowlin T
Antivir Chem Chemother; 1999 Mar; 10(2):79-86. PubMed ID: 10335402
[TBL] [Abstract][Full Text] [Related]
36. (Alkylamino) piperidine bis(heteroaryl)piperizine analogs are potent, broad-spectrum nonnucleoside reverse transcriptase inhibitors of drug-resistant isolates of human immunodeficiency virus type 1 (HIV-1) and select for drug-resistant variants of HIV-1IIIB with reduced replication phenotypes.
Olmsted RA; Slade DE; Kopta LA; Poppe SM; Poel TJ; Newport SW; Rank KB; Biles C; Morge RA; Dueweke TJ; Yagi Y; Romero DL; Thomas RC; Sharma SK; Tarpley WG
J Virol; 1996 Jun; 70(6):3698-705. PubMed ID: 8648704
[TBL] [Abstract][Full Text] [Related]
37. A novel bis-tetrahydrofuranylurethane-containing nonpeptidic protease inhibitor (PI), GRL-98065, is potent against multiple-PI-resistant human immunodeficiency virus in vitro.
Amano M; Koh Y; Das D; Li J; Leschenko S; Wang YF; Boross PI; Weber IT; Ghosh AK; Mitsuya H
Antimicrob Agents Chemother; 2007 Jun; 51(6):2143-55. PubMed ID: 17371811
[TBL] [Abstract][Full Text] [Related]
38. Phenotypic analysis of the sensitivity of HIV-1 to inhibitors of the reverse transcriptase, protease, and integrase using a self-inactivating virus vector system.
Jármy G; Heinkelein M; Weissbrich B; Jassoy C; Rethwilm A
J Med Virol; 2001 Jul; 64(3):223-31. PubMed ID: 11424108
[TBL] [Abstract][Full Text] [Related]
39. HIV-1 acquires resistance to two classes of antiviral drugs through homologous recombination.
Yusa K; Kavlick MF; Kosalaraksa P; Mitsuya H
Antiviral Res; 1997 Dec; 36(3):179-89. PubMed ID: 9477118
[TBL] [Abstract][Full Text] [Related]
40. Delavirdine: a review of its use in HIV infection.
Scott LJ; Perry CM
Drugs; 2000 Dec; 60(6):1411-44. PubMed ID: 11152019
[TBL] [Abstract][Full Text] [Related]
[Previous] [Next] [New Search]